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Summary
Background. — After coronary stenting with drug eluting stents, long-term clinical outcome of
unprotected left main coronary artery disease is unknown, even large scale registries or
randomised trials with coronary artery bypass graft are ongoing. 
Aims. — To report clinical and angiographic results of paclitaxel-eluting stent implantation for
left main coronary artery stenosis (a series of 101 consecutive patients).
Methods. — This report is a prospective study performed to evaluate the immediate and mid-
term clinical and angiographic outcomes of patients undergoing paclitaxel-eluting stent (PES)
implantation for unprotected left main coronary artery (LMCA) stenosis.
From January 2004 to December 2005, 101 consecutive patients were stented with
paclitaxel-eluting stents (the provisional T stenting technique followed by Kissing balloon for
distal left main vessel disease). 
Results. — Mean age was 68.9±11.07 years. 73.3% of patients were male. Acute coronary
syndrome was present in 65% of patients, of whom 22.8% had ST elevation. Distal left main
trunk lesions were present in 87.1% of cases. Three-vessel disease represented 7% of cases.
Angiographic success was obtained in 97.03% of patients with an acute gain of 2.18±0.53mm.
GPIIbIIIa inhibitors were used in only 8.9% of cases. Hospital stay was 7.6 ± 3.7 days. In-hospital
complications were present in 7.9%, with a hospital mortality rate of 2%.
At six month follow-up, the rate of target lesion revascularization (TLR) was 3%, and the rate
for major adverse cardiac events (MACE) was 8.9%. Angiographic control was performed in
88.1% and a late loss of 0.1mm (0.04-0.2mm) was noted. Re-stenosis occurred in 4 patients
(4.5% of cases). 4 patients (4%) died, including 2 from cardiac causes. 
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Conclusion. — Paclitaxel-eluting stent implantation for unprotected left main coronary disease
appears to be safe with high procedural success rate and a low re-stenosis rate at six month-
follow-up.
© 2008 Published by Elsevier Masson SAS.
Résumé
Justification. — L’histoire naturelle des dilatations avec stents des lésions du tronc commun de
la coronaire gauche reste mal connue, en l’absence d’étude à large échelle et de comparaison
randomisée à la chirurgie. 
Objectifs. — Cette étude prospective rapporte les résultats immédiats et à moyen terme de
l’angioplastie avec stent au Paclitaxel du tronc commun coronaire gauche (TCG).
Méthodes. — De Janvier 2004 à Décembre 2005, 101 patients consécutifs ont eu une dilatation
suivi de stenting du TCG avec stent actif au paclitaxel (la technique du T provisional stenting a
été utilisée pour les lésions distales). 
Résultats. — L’âge moyen est de 68.9 ± 11.07 ans avec une prédominance masculine (73.3%).
Un tableau de syndrome coronarien aigu est présent dans 65% des cas dont 22.8% avec élévation
du segment ST. Les lésions de bifurcation du TCG distal sont présentes dans 87.1% des cas.
L’atteinte tritronculaire représente 7% des cas. Le succès angiographique est obtenu dans 97%
des cas avec un gain précoce de 2.18±0.53mm. Le recours aux anti-Gp IIb-IIIa a été nécessaire
dans 8.9% des cas. La durée d’hospitalisation est de 7.6±3.7 jours. Les complications
hospitalières sont présentes dans 7.9% dont 4% d’origine cardio-vasculaire. Le taux de mortalité
hospitalière est de 2%. A 6 mois, le taux de revascularisation de la lésion cible est de 3% et celui
des évènements cardio-vasculaires majeurs est de 8.9%. Le contrôle angiographique (88.1%)
retrouve une perte tardive de 0.1 (0.04-0.2) mm avec 4 cas de resténose soit 4.5%. 4 décès (4%)
surviennent dont 2 d’origine cardiaque. 
Conclusion. — L’angioplastie avec stent actif au paclitaxel du TCG paraît une technique fiable
avec un taux de succès initial important et un faible taux de resténose à 6 mois. 
© 2008 Published by Elsevier Masson SAS.
Significant stenoses of the left main coronary artery (LMCA)
are revealed in 5 to 7% of patients undergoing coronary angio-
graphy (1, 2, 3). Medical treatment alone is associated with a
3 year mortality of 50% (4, 5). Several studies have demonstra-
ted the benefits of surgical treatment with coronary artery
bypass graft (CABG) compared to medical treatment (6, 7).
The results of angioplasty in the early series showed an
increased rate of re-stenosis and acute thrombotic occlusion.
This led various respected bodies (American College of Cardio-
logy and American Heart Association) to favour surgery for
unprotected LMCA revascularization (3, 8). However, since
these recommendations were made, several technological
developments and new drugs have appeared.
With this in mind, a re-evaluation of optimal treatment
for unprotected lesions of the LMCA would seem essential,
especially in the light of recent data from observational stu-
dies suggesting that dilatation of unprotected LMCA with
drug-eluting stents based on sirolimus (Cypher) or pacli-
taxel (Taxus) are safe and effective in reducing the re-ste-
nosis rate compared to bare-metal stents (3, 9,10, 11, 12).
Throughout our study, we attempted to corroborate these
data and to show the feasibility, safety, and immediate and
mid-term results of treating unprotected LMCA stenoses by
systematic implantation of a paclitaxel-eluting stent.
Materials and methods
Patients
From January 2004 to December 2005, 101 consecutive
patients with unprotected LMCA stenosis underwent percu-
Abbreviations
ACS Acute coronary syndrome
ACT Activated cephalin time
AG Acute gain
AVK Antivitamin K (oral anticoagulant)
CABG Coronary artery bypass graft
CK-MB Creatinine phosphokinase MB fraction
CX Circumflex artery
CXO Circumflex artery ostium
DB Daughter branch 
HIV Human immunodeficiency virus
LAD Left anterior descending 
LADO Left anterior descending ostium 
LL Late loss
LMCA Left main coronary artery
MACE Major adverse cardiac events 
MB Mother branch
MI Myocardial infarction
MLD Minimal luminal diameter
OBTO Obtuse-diagonal artery ostium 
PCA Percutaneous coronary angioplasty
PES Paclitaxel-eluting stent
RVD Reference vessel diameter
SD% Stenosis diameter percentage
SL Stenosis length
TIMI Thrombolysis In Myocardial Infarction
TLR Target lesion revascularization 
UFH Unfractionated heparin 
MOTS CLÉS
Tronc coronaire 
gauche;
Angioplastie;
Stent actif;
resténose.
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taneous dilatation with implantation of a paclitaxel-eluting
stent, representing 2.5% of overall activity. The LMCA was
considered to be unprotected when there was no coronary
bypass supplying the LAD or circumflex artery (CX).
The inclusion criteria were symptomatic lesions or angiogra-
phic stenoses > 50% with documented myocardial ischemia.
The decision to perform percutaneous angioplasty was taken if
the coronary anatomy was favourable and the patient or
referring physician requested it, in the absence of surgical
contraindications or significant comorbidity. Patients with a
contraindication to platelet anti-aggregant treatment were
excluded. In keeping with the Helsinki principles, this study
was approved by the local ethics committee, and clear written
consent was obtained for each patient.
Procedure
All of the patients received 160mg aspirin daily for life, and
a loading dose of clopidogrel 300mg 12 hours before the
procedure if they had not already received it, followed by
75mg a day for 6 months in the absence of any instability.
In cases of acute coronary syndrome this double anti-aggre-
gation therapy was continued for a year. Anticoagulation
with a bolus of 55 U/kg of unfractionated heparin was admi-
nistered during the procedure, keeping the ACT > 250
seconds. The use of GPIIbIIIa inhibitors was left to the dis-
cretion of the individual operators. 
The various angioplasty techniques used were carefully
noted (pre-dilatation of the stenosis with a balloon, or rotabla-
tor, followed by stenting; direct stenting; provisional T sten-
ting with kissing balloon). In the case of LMCA bifurcation
angioplasty, provisional T stenting was performed as follows:
angioplasty with positioning of the stent in the distal LMCA and
the ostium of one of the two coronaries (LADO or CXO), known
as the mother branch (MB); the ostium of the other coronary
or daughter branch (DB) was then dilated with a kissing bal-
loon across the stent mesh after having changed the guides
between the two arteries. In cases where the result was
incomplete, a second endoprosthesis was positioned, either at
the distal LMCA and the ostium of the second branch (Y stent),
or solely at the ostium of the second branch (T stent); the pro-
cedure was finished with a final kissing balloon, with the bal-
loons of both stents being inflated simultaneously.
Quantitative coronary angiography
The coronary angiography acquisition and analysis was perfor-
med using a digital system (MEDICAL QCA/CMS MEDIS Imaging
System). After administration of 1mg of molsidomine, the ima-
ges were recorded and then transferred to CD-ROM. The sten-
ted coronary segment was then analysed. For angioplasty of
the LMCA-LADO-CXO bifurcation, the stented segment of the
MB (LMCA-LADO or LMCA-CXO) was analysed as well as the
ostium of the non-stented daughter branch.
Quantification of the segments in two orthogonal projec-
tions was performed whenever possible, before and after
angioplasty, and also during angiographic control at 6
months. The measurements taken were the minimum lumi-
nal diameter (MLD), reference vessel diameter (RVD), ste-
nosis diameter percentage (SD%), and stenosis length (SL).
After angioplasty, quantification was carried out for the
residual stenosis percentage (post-dilatation SD%), post-
dilatation MLD, and the acute gain (AG), defined as post-
dilatation MLD less pre-dilatation MLD. A stenosis percen-
tage less than 30% following dilatation was used to define
primary success. At 6 months, quantification was carried
out for SD%, MLD and late loss (LL), defined as the diffe-
rence between post-dilatation MLD at month 0 and
month 6. A reduction in luminal diameter greater than or
equal to 50% (including complete obstruction) at six months
was considered as significant re-stenosis.
Modes of follow-up
All of the patients were evaluated clinically at 1 and 3 month
consultations, and again in hospital at 6 months, or by tele-
phone for the patients who were followed up for more than
8 months. A check angiography was carried out systemati-
cally during hospitalisation or earlier in the presence of clini-
cal symptoms or evidence of myocardial ischemia.
Definitions
Angiographic success was defined as grade 3 TIMI flow, a
degree of residual stenosis determined by quantitative
angiographic analysis < 30% and the absence of major
adverse cardiac events (MACE). Myocardial infarction was
defined as an elevation of creatinine kinase more than
twice normal with elevation of the CK-MB fraction. Angio-
graphic re-stenosis was defined as more than 50% stenosis in
the mother or daughter branch at angiographic control
after 6 months.
Statistical analysis
The results are presented as a mean and standard deviation
of the mean for quantitative variables. Qualitative varia-
bles are expressed as a percentage. For continuous varia-
bles the data are presented as mean deviation and inter-
quartile range. Statistical analysis was performed using SAS
statistical software (SAS/STAT user’s guide, release 6.12;
SAS Institute Inc).
Results
Patients’ clinical characteristics
The baseline clinical and angiographic data are summarized
in Table 1. A total of 101 patients, predominantly male
(73.3%) underwent LMCA dilatation. The mean age was 68.
92 ± 11.07 years, ranging from 34 to 87 years. Diabetes was
present in 23.8% of our patients. 20% had already had a
revascularization procedure, either CABG or angioplasty.
65% underwent an emergency procedure in the context of
acute coronary syndrome (ACS), of whom 22.8% had ACS
with ST elevation. 73.7% of our patients had a medium or
increased Euroscore risk. The left ventricular ejection frac-
tion was reduced (<40%) in 28.2% of cases. The mean hospi-
tal stay was 7.6 ± 3.7 days. In-hospital complications
occurred in 7.9%, including 4% which were of cardiovascular
origin. The hospital mortality rate was 2%.
Patients’ angiographic characteristics : Table 2
A radial approach was used in 9.9% of cases, and a femoral
approach in 88.1%. The LMCA lesions were mostly distal at
the bifurcation (87.1%). Ostial lesions represented only
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11.9% and median lesions 1% of cases. The distal lesions
usually encompassed the ostium of the left anterior descen-
ding artery (LADO) either alone (57.3%) or in conjunction
with the ostium of the circumflex artery (CXO) (19.1%). In
2.3% of cases the stenosis involved the trifurcation of the
distal LMCA. Coronary involvement was diffuse in 25% of
cases (two-vessel disease: 18%, three-vessel disease: 7%).
Procedural results
The procedural characteristics are summarized in Table 3.
In 79.2% of cases dilatation was performed by direct sten-
Table 1 Clinical characteristics
n %
Number of patients 101 100
Male 74 73.27
Female 27 26.73
Age (years) 68.92 ± 11.07 
(range 34 - 87)
Cardiovascular risk factors
 Hypertension 60 59.41
 Active smoking 56 55.44
 Dyslipidemia 60 59.41
 Diabetes 24 23.76
 Family history 12 11.88
 Body mass index (kg/m²) 26.65 ± 4.16
Previous revascularization 20 20
 Angioplasty 16 16
 Coronary artery bypass graft 3 3
 Mixed 1 1
 None 80 80
Ejection fraction (%) 54.4 ± 18.25
 < 40% 22 28.20
Reason for angioplasty
 Silent ischemia 9 8.91
 Stable angina 18 17.80
 Unstable angina 39 38.61
 Non Q wave MI 6 5.94
 Q wave MI 23 22.77
 Heart failure 6 5.94
Euroscore
 Low risk (1-2) 20 26.31
 Moderate risk (3-5) 38 49.99
 High risk (6 and +) 18 23.70
Pre-PCA troponin (ng/ml) 23.27 ± 64.70
Creatinine (µmol) 100.47 ± 26.70
MI : Myocardial infarction
PCA : Percutaneous coronry angioplasty
Table 2 Angiographic characteristics
n %
Approach
Femoral 89 88.12
Radial 10 9.90
Humeral 2 1.98
LMCA stenosis site
Non-distal LMCA 13 12.87
Distal LMCA 88 87.13
LMCA stenosis combinations
LMCA-LADO 51 57.30
LMCA-CXO 14 15.30
LMCA-LADO-CXO 17 19.10
LMCA-CXO-OBTO 3 3.37
LMCA-CXO-LADO-OBTO 2 2.25
Coronary status
Single vessel 34 34
Two vessel 18 18
Three vessel 7 7
LMCA : Left main coronary artery
LADO : Ostial left anterior descending artery
CXO : Ostial circumflex artery
OBTO : Ostial obtuse diagonal artery
Table 3 Procedure characteristics
n %
Procedure
Pre-dilatation 21 20.79
Direct stenting 80 79.21
LAD stent 70
Secondary branch stent 19
Kissing balloon 81
Simultaneous double kissing 
balloon
6
Provisional T stenting 
(1 stent)
83
T stenting (2 stents) 16
Other technique (Y) 2
Mean inflation pressure (atm) 14.97
Mean stent diameter (mm) 3.45 ± 0.44
Mean stent length (mm) 14.79 ± 1.21
Successful procedure 98
Associated treatment
GPIIbIIIa inhibitor 9 8.91
Aortic counterpulsion 1 0.99
AVK + two antiplatelet agents 5 5
LAD : left anterior descending artery
AVK : Antivitamin K (oral anticoagulant)
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ting. Pre-dilatation for tight stenoses or a very calcified
angiographic appearance was only necessary in 20.8% of
cases. The endoprosthesis was positioned on the LADO in
78.6% of patients. Among the patients with bifurcation
lesions, a final kissing balloon was carried out in 83.5% and
a double kissing balloon (simultaneous inflation of 3 bal-
loons) was necessary in 5.9% of patients. The angioplasty
procedure involved provisional T stenting (single stent
implanted) or 2 stents in the form of a T in 15.8% of
patients. The technique of 2 stents implanted in the form of
a Y was carried out in 2% of cases. The mean diameter of
the stents was 3.45 ± 0.44mm and the mean inflation pres-
sure was 15 atm. GPIIbIIIa inhibitors were only required in
9% of cases.
The overall success rate was 97%. Three failed angioplas-
ties (3%) were recorded (1 stent thrombosis, 1 dissection, 1
no-reflow). Two in-hospital deaths occurred (1 stent throm-
bosis, and 1 retroperitoneal hematoma). The results of
quantitative angiographic analysis are presented in Table 4.
The reference vessel diameter was 3.39 ± 0.42mm. The
minimal luminal diameter increased after angioplasty from
1.2 ± 0.48 to 3.37 ± 0.45mm ; and the stenosis percentage
decreased from 62.4 ± 8.2 to 11 ± 10.2%. The acute gain was
2.18 ± 0.53mm.
Six-month results
Angiographic control at 6-months was performed in
89 patients (88.1%). 12 patients were not checked
(4 deaths, 1 lost to follow-up, 7 due to refusal or co-morbi-
dity). Quantitative angiographic analysis is presented in
Table 5. The degree of stenosis was 14.3 ± 8.5% and the late
loss was 0.1mm (0.04 - 0.2mm). 4 cases of re-stenosis
occurred in the daughter branches in 3 patients, and was
diffuse in a fourth.
9-month results
The mean duration of follow-up was 12.15 ± 3.18 months, and
the clinical follow-up rate was 99.0% (1 patient lost to follow-
up). A total of four patients died (two from cardiac causes):
in addition to the two in-hospital deaths, there was one sud-
den death at 6 months, and one death from septic shock asso-
ciated with HIV infection at 5 months. The cumulative rate of
major adverse cardiac events (Table 6), including death from
all causes, myocardial infarction, heart failure, target lesion
revascularization was 8.9%, with a revascularization rate of
3%. The overall mortality rate was 4%.
Characteristics of patients with re-stenosis
Among the four patients with re-stenosis, three were
asymptomatic. The LMCA lesion was distal in all four cases,
with three-vessel disease in two cases. A T-stenting angio-
plasty had been performed in three cases, with direct sten-
ting in all three. Three patients underwent revasculariza-
tion (1 CABG and 2 angioplasties).
Table 4 Baseline and post-procedure angiographic
data
Reference vessel diameter (mm)
MB 3.39 ± 0.42
DB 3.10 ± 0.54
Lesion length
MB 7.4 ± 2.8 
DB 6.8 ± 2.14
Minimum luminal diameter 
(mm)
MB
Basal 1.2 ± 0.48
Final 3.37 ± 0.45
DB
Basal 2.33 ± 0.39
Final 3.05 ± 0.57
Degree of stenosis (%)
MB
Basal 62.4 ± 8.2
Final 11.05 ± 10.2
DB
Basal 24.73 ± 23.8
Final 7.4 ± 8.5
Acute gain (mm)
MB 2.18 ± 0.53
DB 0.72 ± 0.79
MB : mother branch
DB : daughter branch
Table 5 9-month follow-up
To T>6
months(cumul)
Deaths 2 4
Cardiac 1 2
Non-cardiac 1 2
Myocardial infarction 1 1
Heart failure 0 1
Target lesion 
revascularization
0 3
Others
Stent thrombosis 1 1
Stroke 1 1
Acute renal failure 2 2
Major hemorrhage 1 1
Rhythm disorder 2 2
Major cardiovascular 
adverse events
4 (4.0 %) 9 (8.9%)
Total mortality 2 (1.98%) 4 (3.96%)
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Discussion
The first studies concerning angioplasty of the left main
coronary artery disease without stent implantation often
reported unsatisfactory mid- and long-term results (13, 14),
restricting this procedure to inoperable patients, those with
protected left main trunks (15) and cases of myocardial
infarction with acute occlusion of the left main trunk (16,
17).
The recent development of coronary endoprostheses
together with advances in implantation techniques and
peri-procedural anti-thrombotics have spectacularly redu-
ced thrombotic and hemorrhagic complications following
endoprosthesis implantation. However, intra-stent re-ste-
nosis is the principal factor limiting long term efficacy (12)
and is probably associated with an surplus of late mortality
for LMCA angioplasties (12, 20, 21).
In a recent series reported by the authors (12),
57 patients underwent coronary dilatation with implanta-
tion of bare-metal stents for unprotected LMCA stenoses. At
8 month follow-up, the rate for myocardial infarction was
5.1% and 22.8% for revascularization. The rate of angiogra-
phic re-stenosis was 29.8%.
The advent of drug-eluting stents has resulted in a reduc-
tion in re-stenosis in several series (21, 22, 23). A recent
report from the T-SEARCH registry suggested that implanta-
tion of a paclitaxel-eluting stent for LMCA stenoses has a
favourable effect on reducing re-stenosis (11). Despite
these encouraging results, angioplasty of the main trunk
remains a complicated procedure with very high risks.
Angioplasty of the bifurcation of the distal LMCA is an addi-
tional problem in the treatment of LMCA lesions, because it
combines the risks of LMCA dilatation with the technical dif-
ficulties inherent at the bifurcation. Several techniques
have been described for treating bifurcation lesions (provi-
sional T stenting, Crush stenting…) with the recent intro-
duction of bifurcation-dedicated stents (data insufficient at
present).
Very few studies have evaluated the results of LMCA
angioplasty using drug-eluting stents. Valgimigli et al in the
RESEARCH and T-SEARCH study of 110 patients undergoing
LMCA angioplasty with a drug-eluting stent (sirolimus and
paclitaxel), reported a lower distal stenosis rate (76%) than
in our series. Their dilatation procedure included a higher
pre-dilatation rate (60%) and a kissing balloon technique in
only 20%. The acute gain was lower with a higher late loss.
Re-stenosis in the paclitaxel group was 13% and the rate of
major adverse cardiac events was 29% (11). In another
study, Chieffo et al revealed a MACE rate of 20% and a mor-
tality of 3.5% (10). In a comparison with coronary artery
bypass surgery, a recent study on 123 patients showed a
higher MACE rate in the CABGs group (3).
Our series is distinguished by the patients’ elevated
mean age (68. 92 ± 11.07 years), the inclusion of high-risk
individuals (increased Euroscore risk in 23.7%), and a signi-
ficant rate of left ventricular dysfunction (28.2%). Howe-
ver, we recorded a MACE rate of just 8.9%, a mortality rate
of 4%, and a re-stenosis rate of 4.5%, all of which are rela-
tively low compared to the rates reported in the literature.
In the various reported studies, mortality varies between
0% and 12%. In our work it was only 4%, despite the presence
of high-risk patients and a surplus of LMCA bifurcation
lesions. Although our rate of angiographic control was not
totally exhaustive, we recommend systematic coronary
angiographic control between 6 and 12 months, in view of
the serious and complex nature of main trunk lesions. This
would seem to be more specific and more sensitive than a
stress test or coronary CT. In our study we have attempted
to determine the predictive factors for major adverse car-
diac events. However, no significant relationship was shown
between the different parameters due to our low complica-
tion rate.
Table 6 Angiographic data at 6 months (n=89; 88.1%)
Minimum luminal diameter (mm)
MB 3.16 ± 0.54
DB 2.85 ± 0.77
Degree of stenosis (%)
MB 14.34 ± 8.5
DB 10 ± 12.5
Late loss (mm)
MB 0.1 (0.04-0.2)
DB 0.03 (0-0.16)
Angiographic re-stenosis 4.49%
MB 1
DB 3
MB : mother branch
DB : daughter branch
Table 7 Characteristics of patients with re-stenosis
Age and sex Dilatation strategy LMCA stenosis site Clinical state Re-stenosis site TLR
M, 54 years Provisional T stenting Distal Asymptomatic DB None
M, 84 years T stenting Distal Asymptomatic DB PCA
M, 58 years T stenting Distal Angina Diffuse CABG
M, 73 years T stenting Distal Asymptomatic DB PCA
TLR : target lesion revascularization
MB : mother branch
DB : daughter branch
PCA : Percutaneous coronary angioplasty
CABG : Coronary artery bypass graft
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Limits of this study
Our work concerns a limited number of patients and our
results cannot be generalised to all LMCA lesions. In addi-
tion, the angiographic data were not analysed by a central
laboratory, and the evaluation of the procedure’s final
result was not confirmed by endocoronary echography.
Lastly, the data could have been biased by the individual
experience of the different LMCA angioplasty operators,
and should not be generalised to all interventional centres.
Conclusion
Coronary artery bypass remains the treatment of reference
for lesions of the unprotected left main coronary artery.
However, data from recent studies showing that drug-elu-
ting stents reduce mortality and intra-stent re-stenosis will
probably improve the therapeutic management of these
lesions. Multicenter and randomised trials are required to
compare surgery with drug-eluting stent angioplasty in the
management of these complex left main trunk lesions.
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